Inspire (INSP) Q3 2026 Earnings Call Transcript
Inspire (INSP) reported Q3 2026 revenue of $206.7M, down 7.9% YoY but up 3% sequentially. The company expects stable coding framework in 2027 and a new code in 2028, with strong adoption of Inspire V. Operating loss was $28.7M, and adjusted EPS was $0.14. The company is investing in patient flow optimization and expanding market reach. According to the company, they remain confident in their path to growth.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on revenue, margins, and cash flow, which were not previously public.
Market read
The earnings miss may trigger short‑term sell pressure, while the announced coding improvements could underpin longer‑term growth.
What to watch
The $30M growth‑capacity investment and upcoming 2028 CPT code could support revenue growth beyond 2027.
Background
Inspire Medical Systems reported Q3 2026 results, highlighting a modest sequential revenue increase but a year‑over‑year decline and a net operating loss.
Ticker impact
Q3 2026 earnings released with revenue $206.7M, loss $28.7M and guidance on coding changes.
likely downward pressure as investors digest lower revenue and loss.
Revenue down 7.9% YoY and a net loss of $28.7M signal weaker performance; no positive guidance offsetting the miss.
Market effects
Sleep‑apnea device sector may see short‑term weakness as the market reacts to Inspire's earnings miss.
U.S. healthcare device stocks could face modest pullback.
Limited; impact confined to niche medical‑device space.
Counterpoint
Long‑term investors may view the coding win and new CPT code as a catalyst for future upside despite the near‑term miss.
Key entities
- companyInspire Medical Systems
NASDAQ‑listed developer of hypoglossal nerve stimulation therapy for obstructive sleep apnea.
